首页 | 本学科首页   官方微博 | 高级检索  
检索        

环氧化酶-2及其抑制剂与结直肠癌微血管和淋巴管生成的研究
引用本文:赵士彭,赵发,蔡建辉,卞红磊,桂林.环氧化酶-2及其抑制剂与结直肠癌微血管和淋巴管生成的研究[J].实用肿瘤杂志,2008,23(1):20-23.
作者姓名:赵士彭  赵发  蔡建辉  卞红磊  桂林
作者单位:1. 河北医科大学第三医院肛肠外科,河北医科大学外科教研室,河北,石家庄,050000
2. 河北医科大学第二医院胃肠外科,河北,石家庄,050000
摘    要:目的 探讨环氧化酶-2(COX-2)在结直肠癌组织的表达与肿瘤生物学特征、微血管生成及淋巴管生成的关系及其抑制剂塞来昔布的抗肿瘤作用和机制.方法 应用免疫组化方法 检测64例结直肠癌组织中COX-2的表达、微血管形成及淋巴管生成,分析其相关性及与临床病理参数联系.临床晚期直肠癌患者7例,给予塞来昔布灌肠治疗15天,对活检肿瘤组织微血管及淋巴管进行对比.结果 COX-2的表达与结直肠癌的分期(P=0.003)和组织学类型(P=0.004)相关;COX-2高表达组微血管密度(MVD)和淋巴管密度(LVD)均高于COX-2低表达组(P<0.05).塞来昔布灌肠治疗后直肠癌微血管密度下降,淋巴管密度无差异.结论 COX-2可能通过促进淋巴管及微血管生成参与了结直肠癌的发生与发展.COX-2抑制剂塞来昔布可抑制直肠癌微血管生成.

关 键 词:结肠肿瘤  直肠肿瘤  前列腺素内过氧化物合酶  新生血管化  病理性  塞来昔布/治疗应用  氧化酶  抑制剂  结直肠癌  微血管密度  淋巴管生成  研究  colorectal  adenocarcinoma  lymphangiogenesis  inhibitor  expression  发生与发展  差异  淋巴管密度  相关性  类型  组织学  结果  肿瘤组织  活检  灌肠治疗
文章编号:1001-1692(2008)01-0020-04
收稿时间:2007-07-31
修稿时间:2007年7月31日

Relation of COX-2 expression and its inhibitor with angiogenesis and lymphangiogenesis in colorectal adenocarcinoma
ZHAO Shi-peng ,ZHAO Fa ,CAI Jian-hui ,et al.Relation of COX-2 expression and its inhibitor with angiogenesis and lymphangiogenesis in colorectal adenocarcinoma[J].Journal of Practical Oncology,2008,23(1):20-23.
Authors:ZHAO Shi-peng  ZHAO Fa  CAI Jian-hui  
Abstract:Objective To investigate the relationships among the expression of cyclooxygenase-2(COX-2),microvessel density(MVD) and lymphatic vessel density(LVD) in colorectal adenocarcinoma and to explore the antitumor effects of COX-2 specific inhibitor celecoxib.Methods The expressions of COX-2,MVD and LVD were studied by immunohistochemistry in 64 cases of colorectal adenocarcinomas,and the relationships among COX-2,MVD ,LVD and the clinicopathological characteristics were analyzed.Seven cases of advanced colorectal cancer whose tumor could not be removed,were treated with celecoxib enema twice a day for fifteen days,the changes of LVD and MVD were evaluated.Results The expression of COX-2 was correlated with tumor stage(P=0.003) and histological type(P=0.004) in colorectal carcinoma.MVD and LVD in COX-2 strong expression group were higher than those in COX-2 weak expression group(P<0.05).Treatment of celecoxib enema could reduce MVD but not LVD in colorectal carcinoma.Conclusion COX-2 may be involved in the tumor formation and development of colorectal adenocarcinoma through promotion of angiogenesis and lymphangiogenesis.Celecoxib enema might suppress angiogenesis in colorectal adenocarcinoma.
Keywords:colonic neoplasms  rectal neoplasms  cyclooxygenase  neovascularization  pathologic  celecoxib/ therapeatic use
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号